Open AccessA Phase II Trial of Dual Protease Inhibitor Therapy: Amprenavir in Combination With Indinavir, Nelfinavir, or Saquinavir
Author(s) -
Joseph J. Eron,
Richard Haubrich,
William Lang,
Grace Pagano,
Judith Millard,
Josie Wolfram,
Wendy Snowden,
Louise Pedneault,
Margaret Tisdale
Publication year - 2001
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/00042560-200104150-00008
Subject(s) - amprenavir , saquinavir , nelfinavir , medicine , indinavir , confidence interval , viral load , relative risk , protease inhibitor (pharmacology) , immunology , protease , human immunodeficiency virus (hiv) , antiretroviral therapy , biology , biochemistry , hiv 1 protease , enzyme